Drug Profile
Bupivacaine/meloxicam - Heron Therapeutics
Alternative Names: Bupivacaine/meloxicam extended release; HTX-002/HTX-009; HTX-009/HTX-002; HTX-011; HTX-011A; HTX-011B; Meloxicam/bupivacaine; Meloxicam/bupivacaine extended release; ZYNRELEFLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Heron Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Anilides; Antipyretics; Local anaesthetics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pipecolic acids; Piperidines; Small molecules; Thiazines; Thiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postoperative pain
Most Recent Events
- 12 Mar 2024 Belite Bio announces intention to submit Prior Approval Supplement in Q2 2024
- 12 Mar 2024 Heron Therapeutics anticipates launch of Bupivacaine/meloxicam in the second half of 2024
- 23 Jan 2024 The US FDA approves bupivacaine/meloxicam for Postoperative pain in soft tissue and orthopaedic surgical procedures